⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008535 | 1.00 | — | — | |
| Bromide SCHEMBL1397996 | 0.98 | HRH4 (0.40) | — | |
| Bromide SCHEMBL4608777 | 0.98 | HRH4 (0.40) | — | |
| Hydrochloric Acid SCHEMBL630213 | 0.98 | HRH4 (0.43) | — | |
| Hydrochloric Acid SCHEMBL4609656 | 0.98 | HRH4 (0.43) | — | |
| Hydrochloric Acid SCHEMBL9700185 | 0.98 | HRH4 (0.43) | — | |
| Hydrochloric Acid SCHEMBL7111958 | 0.98 | HRH4 (0.43) | — | |
| SCHEMBL14900011 | 0.84 | DPP4 (0.35) | — | |
| SCHEMBL19187383 | 0.84 | DPP4 (0.35) | — | |
| Choline SCHEMBL27844516 | 0.84 | MEN1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277668-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP THERAPEUTICS INC. | 2024-08-22 | — | — | US | claimed |
| EP-4376835-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP Therapeutics Inc. (US) | 2024-06-05 | — | — | EP | claimed |
| US-20240165082-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | TSP THERAPEUTICS INC. | 2024-05-23 | — | — | US | claimed |
| EP-4340838-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | Paz, Alberto (US) | 2024-03-27 | — | — | EP | claimed |
| WO-2023009261-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | PAZ ALBERTO (US) | 2023-02-02 | — | — | WO | claimed |
| WO-2022245650-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | PAZ ALBERTO (US) | 2022-11-24 | — | — | WO | claimed |
| CN-109069516-A | Small molecule for mouse satellite cell Proliferation | 哈佛学院校长同事会 | 2018-12-21 | — | — | CN | claimed |
| EP-2642988-A1 | METHOD AND COMPOSITION FOR WEIGHT-GAIN MANAGEMENT | Ramot at Tel-Aviv University Ltd (IL) | 2013-10-02 | — | — | EP | claimed |
| WO-2012070043-A1 | METHOD AND COMPOSITION FOR WEIGHT-GAIN MANAGEMENT | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-05-31 | — | — | WO | claimed |
| US-20110144177-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | COLUCID PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | claimed |
| EP-2314571-A2 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | CoLucid Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | claimed |
| US-20100137391-A1 | Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder | MSD K.K. (JP) | 2010-06-03 | — | — | US | claimed |
| EP-1938838-A1 | HISTAMINE H3 AGONIST FOR USE AS THERAPEUTIC AGENT FOR LIPID/GLUCOSE METABOLIC DISORDER | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-02 | — | — | EP | claimed |
| EP-0214058-B1 | PHARMACEUTICAL COMPOSITION CONTAINING HISTAMINE DERIVATIVES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1992-05-06 | — | — | EP | claimed |
| US-4767778-A | HISTAMINE DERIVATIVES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1988-08-30 | — | — | US | claimed |
| EP-0214058-A2 | Pharmaceutical composition containing histamine derivatives | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1987-03-11 | — | — | EP | claimed |
| US-12415790-B2 | GluN2B-subunit selective antagonists of the N-methyl-D-aspartate receptors with enhanced potency at acidic pH | EMORY UNIVERSITY (US) | 2025-09-16 | — | — | US | disclosed |
| WO-2025137730-A1 | N-SUBSTITUTED TRYPTAMINES AND N-SUBSTITUTED LYSERGAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-0214058-A2 | Pharmaceutical composition containing histamine derivatives | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1987-03-11 | — | — | EP | disclosed |
| EP-0204349-A2 | Heteroaromatic amine derivatives, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1986-12-10 | — | — | EP | disclosed |